Faeth Therapeutics, Inc. (FTH) fair value analysis
Nasdaq · Updated 2026-10-19
FTH price how computed
Valuation status
No fair-value estimate yetFTH has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for FTH yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $18.80
- Sector
- Healthcare
- 12-month range
- $7.89–$40.05
- Market cap
- $486M
- From 52-week high
- -53.1%
- Shares outstanding
- 25.8M
- Rank in Healthcare by quality score
- #239 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Faeth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with serious diseases, including oncology and immunology indications. The company is based in the United States and operates as a publicly traded entity on the Nasdaq exchange.
FTH currently ranks #239 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $486M
- P/E (trailing)
- n/m
- Revenue (TTM)
- -$4.85M
- Net margin
- 4030.7%
- EPS (TTM)
- $-141.65
- Debt / equity
- 0.00
- Shares outstanding
- 25.8M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 16 · oversold
- 50-day average
- $31.07
- 200-day average
- $24.74
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-13
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-158.2%)
2026-03 ▼ miss (-21101.6%)
2025-12 ▲ beat (+22.2%)
2025-09 ▲ beat (+11.9%)
2025-06 ▲ beat (+21.8%)
2024-12 ▲ beat (+5.9%)
2024-09 ▲ beat (+9.1%)
2024-06 ▼ miss (-2.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 14 buy · 0 hold · 0 sell (14 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $56.1
- Target vs last price
- +198.4%
What our data shows for FTH
- Shares are trading in the middle of their 12-month price range of $7.89–$40.05.
- The 14-day relative strength index sits at an oversold 16.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- FTH's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the FTH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for FTH in the Healthcare sector shifted this week as the Relative Strength Index moved from neutral territory into oversold zone. The stock's current valuation verdict remains awaiting full valuation. No additional technical indicator changes were recorded for the week.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is FTH stock undervalued?
TickrTrends has no fair-value estimate for FTH yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is FTH's TickrTrends verdict?
FTH is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does FTH compare to other Healthcare stocks?
FTH ranks #239 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is FTH overbought or oversold?
FTH's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does FTH report earnings next?
FTH's next earnings report is scheduled for 2026-11-13, per the published earnings calendar.
Does FTH usually beat earnings estimates?
Over its last 8 reported quarters FTH beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about FTH?
Of 14 analysts covering FTH, 14 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $56.1 (+198.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.